Sham Dholakia, MD, PhD, is the Chief Product Officer at Kyverna Therapeutics and is responsible for the life cycle management of the company’s pipeline of programs. Sham brings more than 20 years of experience in clinical development as both a trained surgeon and pharmaceutical executive to Kyverna and is also an expert in deploying artificial intelligence (AI) to improve pharmaceutical and diagnostic development programs.

Sham joined Kyverna in 2024, as the life cycle leader for the Company’s stiff person syndrome (SPS) and lupus nephritis programs as well as the long-term follow-up initiative. Prior to Kyverna, Sham served as the Chief Medical Officer at Gen1E Lifesciences Inc., a clinical stage, multi-target company with a unique AI platform, where he led a team using AI to develop novel therapeutics. He was also the Chief Medical Officer of CareDx, Inc., a company dedicated to improving the lives of organ transplant patients through non-invasive diagnostics, where he helped to grow the company to over a $5 billion valuation at its peak. Sham practiced medicine as a surgeon with the National Health System in the United Kingdom for 10 years, specializing in general, vascular, and transplant surgeries and has led the delivery of more than 100 peer-reviewed papers and 300 abstracts. While working as a surgeon, Sham also served in the military and as a consultant at GE Healthcare.

Sham received his medical degree from Imperial College London and received his doctorate in Surgical Science and Immunology from the University of Oxford.